1.Proton pump inhibitors have been extensively used for the treatment of ailments due to increased gastric acid secretion such as peptic ulcers, gastroesophageal reflux disease, etc. 2.There are several approved drugs in the proton pump inhibitor class with the latest entries representing single enantiomer drugs of the previously approved racemic drugs. 3.Despite having a high degree of structural resemblance, rabeprazole, was shown to possess some unique differentiation from other drugs in the class. One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition. 4.The review was aimed to provide pharmacokinetic data of rabeprazole from several clinical studies including drug–drug interaction studies where rabeprazole was either a perpetrator drug or victim drug. 5.Additional perspectives on therapy considerations due to the unique metabolic disposition of rabeprazole including the possible issues related to chirality were provided.
- drug interaction
ASJC Scopus subject areas
- Health, Toxicology and Mutagenesis